RTOG-0615
Terminated
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) For Locally or Regionally Advanced Nasopharyngeal Cancer
Principal Investigator
Nancy Lee
Status
Terminated
Date Opened To Accrual
December 13, 2006
Date Closed To Accrual
February 5, 2009
Date of Study Termination
May 14, 2018
Disease Site
Head and Neck [HN] Head and Neck
Phase
II
Developmental Therapeutics
No
Primary Objective
To evaluate the safety and tolerability of bevacizumab (BV) plus chemoradiation
Data Collection Notice:
Data for this trial is being collected via the NRG/RTOG Data Center.
Patient Population
Confirmed histopathologic diagnosis of nasopharyngeal carcinoma: Types WHO I-IIb/III, Stage IIB-IVB; no head and neck surgery of the primary tumor or lymph nodes, except for incisional or excisional biopsies
Target Accrual
46
Protocol Document
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.
-
Share this study.
-
-
-
-
